MCID: NRG002
MIFTS: 55

Neurogenic Bladder

Categories: Nephrological diseases, Neuronal diseases

Aliases & Classifications for Neurogenic Bladder

MalaCards integrated aliases for Neurogenic Bladder:

Name: Neurogenic Bladder 12 29 6 15
Neurogenic Dysfunction of the Urinary Bladder 12
Neurogenic Urinary Bladder Disorder 12
Urinary Bladder, Neurogenic 43
Neurogenic Urinary Bladder 71
Neuropathic Bladder 12
Bladder Neurogenic 54

Classifications:



External Ids:

Disease Ontology 12 DOID:12143
ICD9CM 34 596.54
MeSH 43 D001750
NCIt 49 C79696
SNOMED-CT 67 397732007
UMLS 71 C0005697

Summaries for Neurogenic Bladder

MalaCards based summary : Neurogenic Bladder, also known as neurogenic dysfunction of the urinary bladder, is related to lethal congenital contracture syndrome 2 and vesicoureteral reflux 1, and has symptoms including seizures, vertigo and dysuria. An important gene associated with Neurogenic Bladder is EBF3 (EBF Transcription Factor 3), and among its related pathways/superpathways are CREB Pathway and Calcium signaling pathway. The drugs Acetylcholine and Silodosin have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, testes and brain, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 74 Neurogenic bladder dysfunction, or neurogenic bladder, refers to urinary bladder problems due to disease... more...

Related Diseases for Neurogenic Bladder

Diseases related to Neurogenic Bladder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 354)
# Related Disease Score Top Affiliating Genes
1 lethal congenital contracture syndrome 2 32.3 PIP5K1C ERBB3
2 vesicoureteral reflux 1 31.3 UPK3A HPSE2 EBF3
3 low compliance bladder 31.0 P2RX3 NGF CHRM2
4 detrusor sphincter dyssynergia 30.5 TRPV1 P2RX3 P2RX2 NGF
5 bladder neck obstruction 30.4 KLK3 BCL2L10
6 pyuria 30.1 UPK3A KLK3
7 urethral stricture 30.0 KLK3 BCL2L10
8 bladder calculus 29.9 KLK3 BCL2L10
9 glandular cystitis 29.9 UPK3A KLK3
10 radiation cystitis 29.7 UPK3A P2RX1 KLK3
11 cystitis 29.6 UPK3A TRPV1 TACR1 P2RX3 NGF
12 pain agnosia 29.4 TRPV1 TACR1 NGF
13 chronic cystitis 29.3 UPK3A TRPV1 P2RX3 NGF
14 interstitial cystitis 29.2 UPK3A TRPV1 TACR1 P2RX3 NGF
15 hinman syndrome 11.9
16 urofacial syndrome 1 11.9
17 sacral defect with anterior meningocele 11.6
18 polyglucosan body neuropathy, adult form 11.4
19 adult polyglucosan body disease 11.4
20 lateral meningocele syndrome 11.3
21 lethal congenital contracture syndrome 3 11.3
22 peroxisome biogenesis disorder 10b 11.3
23 leukodystrophy, progressive, early childhood-onset 11.3
24 giant axonal neuropathy 11.3
25 cog5-congenital disorder of glycosylation 11.3
26 spinal cord injury 11.0
27 acute cystitis 10.8
28 myelomeningocele 10.8
29 neural tube defects 10.8
30 hydronephrosis 10.7
31 bacteriuria 10.6
32 pyelonephritis 10.5
33 bladder disease 10.5
34 paraplegia 10.4
35 constipation 10.4
36 spasticity 10.4
37 multiple sclerosis 10.3
38 bladder cancer 10.3
39 quadriplegia 10.3
40 herpes zoster 10.3
41 prostatic hypertrophy 10.3
42 urinary tract obstruction 10.3
43 myelitis 10.3
44 lipomatosis, multiple 10.3
45 pleomorphic lipoma 10.3
46 impotence 10.3
47 kidney disease 10.3
48 neuropathy 10.3
49 end stage renal disease 10.2
50 spinal shock 10.2

Comorbidity relations with Neurogenic Bladder via Phenotypic Disease Network (PDN): (show all 27)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Alzheimer Disease
Bladder Neck Obstruction Cystitis
Decubitus Ulcer Deficiency Anemia
Diabetic Polyneuropathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Familial Atrial Fibrillation Heart Disease
Hydronephrosis Hypertension, Essential
Hypothyroidism Multiple Sclerosis
Osteoporosis Paralytic Ileus
Paraplegia Parkinson Disease, Late-Onset
Peripheral Vascular Disease Prostatic Hypertrophy
Protein-Energy Malnutrition Schizophreniform Disorder
Swallowing Disorders Transient Cerebral Ischemia
Urethral Stricture

Graphical network of the top 20 diseases related to Neurogenic Bladder:



Diseases related to Neurogenic Bladder

Symptoms & Phenotypes for Neurogenic Bladder

UMLS symptoms related to Neurogenic Bladder:


seizures, vertigo, dysuria, pain, meningism, reflex, abnormal, urgency of micturition, neurobehavioral manifestations, neuromuscular manifestations

MGI Mouse Phenotypes related to Neurogenic Bladder:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.15 ACER3 CACNA1A CHRM2 COL6A2 ERBB3 GBE1
2 homeostasis/metabolism MP:0005376 10.1 ACER3 CACNA1A CHRM2 ERBB3 GBE1 HPSE2
3 cardiovascular system MP:0005385 10.06 CHRM2 ERBB3 GBE1 KLK3 NGF P2RX1
4 integument MP:0010771 9.81 CACNA1A CHRM2 ERBB3 NGF P2RX3 PEX3
5 nervous system MP:0003631 9.73 ACER3 CACNA1A CHRM2 EBF3 ERBB3 GBE1
6 respiratory system MP:0005388 9.17 CACNA1A CHRM2 ERBB3 GBE1 P2RX2 P2RX3

Drugs & Therapeutics for Neurogenic Bladder

Drugs for Neurogenic Bladder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 108)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
2
Silodosin Approved Phase 4 160970-54-7
3
Morphine Approved, Investigational Phase 4 57-27-2 5288826
4
Belladonna Approved, Experimental Phase 4
5
Mirabegron Approved Phase 4 223673-61-8 9865528
6
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
7
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
8
Cefixime Approved, Investigational Phase 4 79350-37-1 5362065 54362
9
Fosfomycin Approved Phase 4 23155-02-4 446987
10
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
11
Ceftriaxone Approved Phase 4 73384-59-5 5361919 5479530
12
Oxybutynin Approved, Investigational Phase 4 5633-20-5 4634
13
Methenamine Approved, Vet_approved Phase 4 100-97-0 4101
14
Fidaxomicin Approved Phase 4 873857-62-6
15
Vancomycin Approved Phase 4 1404-90-6 14969 441141
16 Cholinergic Agents Phase 4
17 Cholinergic Antagonists Phase 4
18 Neurotransmitter Agents Phase 4
19 Adrenergic Agents Phase 4
20 Adrenergic alpha-1 Receptor Antagonists Phase 4
21 Botulinum Toxins Phase 4
22 Narcotics Phase 4
23 Analgesics Phase 4
24 Opiate Alkaloids Phase 4
25 Analgesics, Opioid Phase 4
26 Adrenergic beta-Agonists Phase 4
27 Adrenergic Agonists Phase 4
28 Adrenergic beta-3 Receptor Agonists Phase 4
29 Solifenacin succinate Phase 4 242478-38-2
30 penicillins Phase 4
31 Parasympatholytics Phase 4
32 Muscarinic Antagonists Phase 4
33 Antibiotics, Antitubercular Phase 4
34 Methenamine mandelate Phase 4
35 Methenamine hippurate Phase 4
36 Anti-Infective Agents Phase 4
37 Anti-Bacterial Agents Phase 4
38
Propiverine Approved, Investigational Phase 3 60569-19-9 4942
39
Tamsulosin Approved, Investigational Phase 2, Phase 3 106133-20-4 129211
40
Fesoterodine Approved Phase 3 286930-02-7, 286930-03-8 6918558
41
Alfuzosin Approved, Investigational Phase 3 81403-80-7 2092
42
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
43
Ofloxacin Approved Phase 3 82419-36-1 4583
44
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
45 Cranberry Approved, Investigational Phase 3
46
Midazolam Approved, Illicit Phase 3 59467-70-8 4192
47
tannic acid Approved Phase 2, Phase 3 1401-55-4
48
Benzocaine Approved, Investigational Phase 2, Phase 3 94-09-7, 1994-09-7 2337
49 Octenidine Investigational Phase 2, Phase 3 71251-02-0
50 Mitogens Phase 3

Interventional clinical trials:

(show top 50) (show all 170)
# Name Status NCT ID Phase Drugs
1 Phase 4 Study of the Effect of Botulinum-A Toxin Injected in Neurogenic Overactive Bladders of Children Born With Myelomeningocele Unknown status NCT00175123 Phase 4 Botulinum A toxin
2 Randomized Placebo-Controlled Trial of Gentamicin Bladder Instillation for the Prevention of Urinary Tract Infection in Adults at High Risk for Cystitis Due to Intermittent Catheterization Unknown status NCT01884467 Phase 4 Gentamicin;Placebo
3 A 12-week, Open-label, Multi-center Study to Evaluate the Clinical Efficacy and Safety of Silodosin on Voiding Dysfunction Associated With Neurogenic Bladder Completed NCT01228370 Phase 4 silodosin
4 Reduction of Bladder Injection Pain With Belladonna Opiate Suppository: A Randomized, Double-Blind, Placebo-Controlled Trial (ROBIN Trial) Completed NCT02600715 Phase 4 Onabotulinumtoxin A (BoNT);belladonna;Morphine;Placebo;Active B&O suppository of belladonna
5 Quality of Life Intermittent Catheter Study - A Prospective, Randomized, Cross-over, Multicenter Study Comparing Quality of Life Using Compact Versus Standard Urinary Intermittent Catheters Completed NCT01523743 Phase 4
6 A Randomized, Multicenter, Parallel Group Study to Evaluate Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder Completed NCT01388413 Phase 4 Weekly Oral Cyclic Antibiotic programme
7 A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity Completed NCT00629642 Phase 4 Solifenacin Succinate;Solifenacin Succinate;Oxybutynin Hydrochloride;Placebo
8 Onabotulinum Toxin Type A (BTX-A) For Treatment of Neurogenic Overactive Bladder Due to Parkinson's Disease: Safety and Efficacy Completed NCT01421719 Phase 4 Cystoscopic injection of Botox into the urinary bladder
9 A Prospective, Randomized, Parallel-group, Multi-center Study to Compare the Occurrence of Urinary Tract Infections in Patients With Spinal Cord Injury Using Either Coated or Uncoated Intermittent Catheters. Completed NCT00318591 Phase 4
10 A Multi-center, Open-label, Dose-titration Pilot Study Evaluating the Efficacy and Safety of Oxybutynin Transdermal Systems in Patients With Neurogenic Bladder Resulting From Spinal Cord Injury Completed NCT00224029 Phase 4 Oxybutynin transdermal system
11 Effect of Botox Treatment for Neurogenic Detrusor Overactivity on the Prevention of Autonomic Dysreflexia Following Spinal Cord Injury Completed NCT02298660 Phase 4 BOTOX
12 Short and Long Term Exposure to Unique, Time-Varying Pulsed Electro-Magnetic Fields in Refractory Carpal Tunnel Syndrome (Cts): A Randomized, Placebo-Controlled Trial With Secondary Bayesian Modification Completed NCT00277563 Phase 4
13 The EDGE Consortium: A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Percutaneous Nephrolithotomy: Part 1 Completed NCT02384200 Phase 4 nitrofurantoin monohydrate/macrocrystalline capsules;ampicillin;gentamicin;vancomycin;ceftriaxone
14 Efficacy and Safety of Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder Completed NCT03558919 Phase 4 Mirabegron 25mg;Solifenacin Succinate 5 MG
15 A Two-part, Multicenter, Dose-titration Study Evaluating Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Oxybutynin Chloride 10% Gel for Treatment of Detrusor Overactivity Associated Neurological Condition in Pediatric Patients Recruiting NCT01192568 Phase 4 Oxybutynin
16 The Effect of Methenamine Hippurate to Reduce Antibiotic Prescribing Due to New Episodes of Urinary Tract Infections (UTI) in Elderly Women With Recurrent UTI - a Triple- Blinded, Randomized Placebo-controlled Phase IV Study Enrolling by invitation NCT04077580 Phase 4 Methenamine Hippurate 1000 MG
17 Role of Fidaxomicin in a Patient Population With Problematic Clostridium Difficile Infection Terminated NCT02355938 Phase 4 Fidaxomicin 200 mg;Placebo;Vancomycin
18 Antiseptic-coated Intermittent Urinary Catheter: Efficacy and Feasibility of Neurogenic Bladder Management and Prevention of Catheter-associated Urinary Tract Infections in Children Unknown status NCT02697162 Phase 2, Phase 3 Octenidine chloride
19 The Effect of L-carnitine on the Prevention of Renal Scarring in Children With Acute Pyelonephritis Unknown status NCT02007889 Phase 3 L-carnitine
20 Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children Unknown status NCT02192580 Phase 3 Omega-3
21 A Double-Blind, Randomized Study of the Safety and Efficacy of OnabotulinumtoxinA (OnaBoNT-A) Versus Oral Oxybutynin in Spinal Cord Injured Patients With Neurogenic Detrusor Overactivity (Protocol Number 11-09-10-04) Unknown status NCT01050114 Phase 3 onaBoNT-A;Oxybutynin ER
22 Efficacy and Tolerability of Propiverine Hydrochloride Extended Release (ER) Compared to Immediate Release (IR) in Patients With Neurogenic Detrusor Overactivity. A Randomized, Double Blind, Parallel Group, Multicenter Clinical Trial Completed NCT01530620 Phase 3 Propiverine hydrochloride ER (extended release);Propiverine hydrochloride IR (immediate release)
23 A Phase IIb/III, Multi-centre, Double-blind, Randomised, Placebo-controlled, Dose Ranging Study of Tamsulosin Hydrochloride (Low, Medium and High Dose) as Treatment in Children With Neuropathic Bladder for Three Months Completed NCT00796614 Phase 2, Phase 3 tamsulosin hydrochloride;Placebo
24 A Pilot Study Comparing the Effects of Botulinum Toxin A and Standard Oxybutynin Therapy as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder Completed NCT01716624 Phase 3 Oxybutynin;Botulinum Toxin A injection
25 A 24-WEEK RANDOMIZED, OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FESOTERODINE IN SUBJECTS AGED 6 TO 17 YEARS WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED WITH A NEUROLOGICAL CONDITION (NEUROGENIC DETRUSOR OVERACTIVITY) Completed NCT01557244 Phase 3 Fesoterodine PR 4 mg;Fesoterodine PR 8 mg;Fesoterodine PR 8 mg;Oxybutynin;Fesoterodine PR;Fesoterodine BIC 2 mg;Fesoterodine BIC 4 mg
26 LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY OF FESOTERODINE IN JAPANESE PEDIATRIC SUBJECTS WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED WITH A NEUROLOGICAL CONDITION (NEUROGENIC DETRUSOR OVERACTIVITY) WHO HAVE COMPLETED 24 WEEKS TREATMENT IN STUDY A0221047 Completed NCT02501928 Phase 3 Fesoterodine PR 4 mg;Fesoterodine PR 8 mg;Fesoterodine BIC 2 mg;Fesoterodine BIC 4 mg
27 Four-week, Open-label, Multicenter, Randomized, Parallel-group Study to Investigate the Pharmacokinetics, Safety, Tolerability and the Effects on Leak Point Pressure of Two Oral Doses of Alfuzosin (0.1 mg/kg/Day; 0.2 mg/kg/Day) in Children and Adolescents 2 to 16 Years-of-age With Elevated Detrusor Leak-point Pressure of Neuropathic Etiology Completed NCT00629720 Phase 3 alfuzosin (SL770499)
28 12-week, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy, Pharmacodynamic and Safety of 2 Doses of Alfuzosin (0.1 mg/kg/Day, 0.2 mg/kg/Day) in the Treatment of Children and Adolescents 2-16 Years With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology Followed by a 40-week Open-label Extension Completed NCT00549939 Phase 3 Alfuzosin;Placebo
29 Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS) Completed NCT01600716 Phase 3 Placebo (Normal Saline)
30 12-week, Multicenter, Open-label, Non-comparative Study to Investigate Pharmacodynamic and Safety of Alfuzosin 0.2 mg/kg/Day in the Treatment of Children and Adolescents 2 - 16 Years of Age With Hydronephrosis Associated With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology Followed by a 40-week Open-label Extension Completed NCT00576823 Phase 3 Alfuzosin
31 A Multicenter, Double-Blind, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Ciprofloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults Completed NCT00258089 Phase 3 Levofloxacin
32 Effectiveness of Pentoxifylline in Attenuating Neurological Disease Associated With HTLV-1 and Negative Modulator of Pathological Immune Response. Completed NCT01472263 Phase 3 Pentoxifylline;Placebo
33 Prospective, Randomized, Double-blind, Placebo-controlled Study on Parallel Groups Evaluating the Efficacy and Safety of Cranberry (Vaccinium Macrocarpon) in Prevention of Urinary Tract Infections in Multiple Sclerosis Patients. Completed NCT00280592 Phase 3 Cranberry;Placebo
34 Oxybutynin for Post-surgical Bladder Pain and Urgency Recruiting NCT03952299 Phase 3 Oxybutynin Transdermal Patch;Oral Oxybutynin
35 Dual Benefits of Vaginal Estriol: Improved Urogenital Health and Re-myelination in Relapsing Remitting Multiple Sclerosis (RRMS) Recruiting NCT03774407 Phase 2, Phase 3 vaginal estriol
36 The Effect of Gentamicin Intravesical Installations on Decreasing Urinary Tract Infections in Patients With Neurogenic Bladder After Spinal Cord Injury: A Clinical Trial Active, not recruiting NCT03503513 Phase 2, Phase 3 Gentamicin Sulfate;Saline
37 Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters Not yet recruiting NCT04323735 Phase 3 Culturelle 10 Billion CFU Capsule
38 Intravesical Lactobacillus to Reduce Urinary Symptoms After Spinal Cord Injury Not yet recruiting NCT04373512 Phase 3 Culturelle 10 Billion CFU Capsule (2 doses);Culturelle 10 Billion CFU Capsule (4 doses)
39 Use of Novel Human Milk Prebiotics to Improve the Quality of Life for Spinal Cord Injury Patients With Bowel and Bladder Dysfunction Not yet recruiting NCT03987126 Phase 3
40 A Double Blind, Randomized Placebo Controlled Trial Evaluating the Urodynamic and Clinical Efficacy of Mirabegron Among Neurogenic Bladder Patients Terminated NCT02044510 Phase 2, Phase 3 Mirabegron;Placebo
41 Injection of Botulinum Toxin Type A Into the External Urethral Sphincter for Male Patients Suffering From Chronic Prostatitis/Chronic Pelvic Pain Syndrome (NIH Cat. III): a Prospective, Double-blind and Placebo-controlled Clinical Trial Terminated NCT00464373 Phase 3 Botulinum Toxin Type A;Placebo
42 Effect of Tamsulosin vs Prazosin in Treatment of Female Voiding Dysfunction Unknown status NCT00602186 Phase 1, Phase 2 tamsolusin;prazosin
43 A Clinical Trial to Determine the Extent to Which Probiotic Therapy Reduces Side Effects of Antibiotic Prophylaxis in Pediatric Neurogenic Bladder Patients With a History of Recurrent Urinary Tract Infections Unknown status NCT02044965 Phase 1, Phase 2 Probiotic
44 An Uncontrolled, Open-label, Titration, Long-term Safety (up to 12 Months) and Efficacy Study of Tamsulosin Hydrochloride in Children With Neuropathic Bladder, With a Randomized Pharmacokinetic Sub-study Investigating Low, Medium and High Dose Ranges. Completed NCT00340704 Phase 2 tamsulosin hydrochloride
45 Prevention of Recurrent Symptomatic Urinary Tract Infections in Participants With Chronic Neurogenic Bladder Dysfunction: A Mixed Method Study Completed NCT02591901 Phase 2 Uro vaxom
46 Self-management of Urine Flow in Long-term Urinary Catheter Users Completed NCT00883220 Phase 2
47 Multifaceted Treatment of Catheter-related Urinary Tract Infection Completed NCT00732238 Phase 2
48 A Multicenter, Double-blind, Crossover Design, Pilot Study to Evaluate the Effect of NVC-422 Catheter Irrigation on Urinary Catheter Patency Completed NCT01243125 Phase 2 NVC-422, 0.2%;Sterile normal saline, 0.9%
49 Lumbar to Sacral Ventral Nerve Re-Routing Completed NCT00378664 Phase 2
50 A Treatment Trial of Triheptanoin in Patients With Adult Polyglucosan Body Disease - A Randomized Controlled Study Completed NCT00947960 Phase 2 Triheptanoin

Search NIH Clinical Center for Neurogenic Bladder

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Baclofen
Bethanechol
Bethanechol Chloride
Hyoscyamine
Hyoscyamine hydrobromide
Hyoscyamine Sulfate
oxybutynin
Oxybutynin chloride

Cochrane evidence based reviews: urinary bladder, neurogenic

Genetic Tests for Neurogenic Bladder

Genetic tests related to Neurogenic Bladder:

# Genetic test Affiliating Genes
1 Neurogenic Bladder 29

Anatomical Context for Neurogenic Bladder

MalaCards organs/tissues related to Neurogenic Bladder:

40
Spinal Cord, Testes, Brain, Kidney, Prostate, Colon, Heart

Publications for Neurogenic Bladder

Articles related to Neurogenic Bladder:

(show top 50) (show all 4082)
# Title Authors PMID Year
1
Peripheral tachykinin receptors as potential therapeutic targets in visceral diseases. 61 54
12783571 2003
2
Caudal regression syndrome (Currarino syndrome) with chromosom mutation 9. 61
32550955 2020
3
Malignancy after Augmentation Enterocystoplasty: A Nationwide Study of Natural History, Prognosis and Oncogene Panel Analysis. 61
31957550 2020
4
Botulinum toxin in low urinary tract disorders - over 30 years of practice (Review). 61
32509003 2020
5
Overactive bladder and urgency urinary incontinence in men undergoing artificial urinary sphincter placement. 61
32339308 2020
6
Iatrogenic bladder rupture in individuals with disability related to spinal cord injury and chronic indwelling urethral catheters. 61
32513945 2020
7
Neurological Complications and Associated Risk Factors in Children Affected with Chronic Kidney Disease. 61
32521637 2020
8
Has the use of preoperative urodynamics for stress urinary incontinence surgery changed following the VALUE study? 61
32559352 2020
9
Case Report: Recurrent Pyometra in an Adolescent. 61
32574600 2020
10
Urodynamic findings during the filling phase in neurogenic bladder patients with or without vesicoureteral reflux who have undergone sacral neuromodulation. 61
32282088 2020
11
URINARY TRACT ANOMALIES IN PATIENTS WITH ANORECTAL MALFORMATIONS: THE ROLE OF SCREENING AND CLINICAL FOLLOW-UP. 61
32525076 2020
12
Intravesical hyaluronic acid treatment in recurrent urinary tract infections in children with spina bifida and neurogenic bladder. 61
32197933 2020
13
Complications in adulthood for patients with paediatric genitourinary reconstruction. 61
32529452 2020
14
Vesicocutaneous fistula: continent vesicostomy, an easier route for comfortable clean intermittent catheterization. 61
32171665 2020
15
Cauda equina syndrome: false-positive diagnosis of neurogenic bladder can be reduced by multichannel urodynamic study. 61
31907657 2020
16
Development and validation of a bladder trabeculation grading system in pediatric neurogenic bladder. 61
32247670 2020
17
Re: Reasons for Cessation of Clean Intermittent Catheterization after Spinal Cord Injury: Results from the Neurogenic Bladder Research Group Spinal Cord Injury Registry. 61
32567969 2020
18
Neurogenic bladder symptom score: Polish translation, adaptation and validation of urinary disorder-specific instrument for patients with neurogenic lower urinary tract dysfunction. 61
32515531 2020
19
Contemporary multicenter outcomes of continent cutaneous ileocecocystoplasty in the adult population over a 10-year period: A Neurogenic Bladder Research Group study. 61
32506711 2020
20
Use of oral third generation cephalosporins and quinolones and occurrence of antibiotic-resistant strains in the neurogenic bladder (NB) outpatient setting: a retrospective chart audit. 61
31965059 2020
21
Anterior Urethral Valve - A Commonly Misdiagnosed Entity in Adolescent Boys. 61
32087211 2020
22
Diet in neurogenic bowel management: A viewpoint on spinal cord injury. 61
32523306 2020
23
Stepwise Description and Outcomes of Bladder Neck Sparing Robot-Assisted Simple Prostatectomy. 61
32183554 2020
24
The correlation between diffusion tensor imaging of the sacral cord and bladder contractility in people with tetraplegia. 61
32415223 2020
25
Change in urodynamic pattern and incidence of urinary tract infection in patients with traumatic spinal cord injury practicing clean self-intermittent catheterization. 61
30277852 2020
26
The intravesical injection of highly purified botulinum toxin for the treatment of neurogenic detrusor overactivity. 61
32432536 2020
27
Development and Validation of Symptom Score for Total Bladder-Bowel Dysfunction; Subscales for Overactive Bladder and Dysfunctional Voiding. 61
32469626 2020
28
In Silico Subtractive Proteomics Approach for Identification of Potential Drug Targets in Staphylococcus saprophyticus. 61
32455889 2020
29
Stem Cell Therapy for Neurogenic Bladder After Spinal Cord Injury: Clinically Possible? 61
32482052 2020
30
[Course of neurogenic bladder dysfunction in patients with spinal cord injury under homeopathic treatment]. 61
32424576 2020
31
Indwelling catheterization, renal stones, and hydronephrosis are risk factors for symptomatic Staphylococcus aureus-related urinary tract infection. 61
32363449 2020
32
Dialysis in Pregnancy: Role of the Underlying Cause of Renal Failure on Peripartum Outcomes. 61
31910463 2020
33
The incidence and effect of tethered cord release for tethered cord syndrome in patients with myelomeningocele: a population-based study. 61
32470933 2020
34
Frequency of patient-reported UTIs is associated with poor quality of life after spinal cord injury: a prospective observational study. 61
32409777 2020
35
Urological Evaluation of Tethered Cord Syndrome. 61
32392667 2020
36
Re: Reasons for Cessation of Clean Intermittent Catheterization after Spinal Cord Injury: Results from the Neurogenic Bladder Research Group Spinal Cord Injury Registry. 61
32421407 2020
37
Re: A Cross-Sectional Study of the Catheter Management of Neurogenic Bladder after Traumatic Spinal Cord Injury. 61
32396432 2020
38
Urinary Symptoms and Bladder Dysfunction in Patients with Neuromyelitis Optica Spectrum Disorders: Evaluation with Urodynamics and Management. 61
32367978 2020
39
Short-term outcomes of laparoscopic lateral pelvic node dissection for advanced lower rectal cancer. 61
32246236 2020
40
The Stockholm Spinal Cord Uro Study: 2. Urinary tract infections in a regional prevalence group: frequency, symptoms and treatment strategies. 61
32148149 2020
41
Use of a Closed Diurnal Indwelling Catheter for Patients With Spinal Cord Disorders: A Pilot Study. 61
32320790 2020
42
Inappropriate initial urinary catheter placement among older Chinese hospital inpatients: An observational study. 61
31793146 2020
43
Is baseline routine renal ultrasound indicated for all MS patients? 61
31611266 2020
44
Hiccups triggered by bladder filling after bilateral pontine hemorrhage: A case report. 61
32243359 2020
45
Introducing a novel experimental model of bladder transplantation in mice. 61
32282990 2020
46
The creation and validation of a short form of the Neurogenic Bladder Symptom Score. 61
32196732 2020
47
How early is early? Effect of oxybutynin on bladder dynamics within the first year of life in patients with spina bifida. 61
32115375 2020
48
Effect of electroacupuncture on diabetic neurogenic bladder: A randomized controlled trial protocol. 61
32332636 2020
49
Spectrum of diabetic neuropathies. 61
32206478 2020
50
Utilization of Augmentation Cystoplasty for Myelomeningocele Patients Remained Stable Over the Past Decade. 61
32360629 2020

Variations for Neurogenic Bladder

ClinVar genetic disease variations for Neurogenic Bladder:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 EBF3 NM_001005463.3(EBF3):c.512G>A (p.Gly171Asp)SNV Pathogenic 375375 rs1057519437 10:131755564-131755564 10:129957300-129957300
2 CACNA1A NM_001127221.1(CACNA1A):c.6128C>T (p.Thr2043Met)SNV Uncertain significance 386521 rs563345694 19:13323262-13323262 19:13212448-13212448
3 COL6A2 NM_001849.3(COL6A2):c.2008A>G (p.Thr670Ala)SNV Uncertain significance 598977 rs753298014 21:47545737-47545737 21:46125823-46125823

Expression for Neurogenic Bladder

Search GEO for disease gene expression data for Neurogenic Bladder.

Pathways for Neurogenic Bladder

Pathways related to Neurogenic Bladder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.58 TRPV1 P2RX3 P2RX2 P2RX1 NGF ERBB3
2
Show member pathways
11.47 TACR1 P2RX3 P2RX2 P2RX1 ERBB3 CHRM2
3
Show member pathways
11.42 P2RX3 P2RX2 CACNA1A

GO Terms for Neurogenic Bladder

Cellular components related to Neurogenic Bladder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.13 UPK3A TRPV1 TACR1 PIP5K1C PEX3 P2RX3
2 cell GO:0005623 9.8 TRPV1 TACR1 P2RX3 P2RX2 CMA1 CACNA1A
3 integral component of plasma membrane GO:0005887 9.7 TRPV1 TACR1 P2RX3 P2RX2 P2RX1 ERBB3
4 neuronal cell body GO:0043025 9.35 TRPV1 P2RX3 P2RX2 CHRM2 CACNA1A
5 integral component of nuclear inner membrane GO:0005639 8.8 P2RX3 P2RX2 P2RX1

Biological processes related to Neurogenic Bladder according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 ion transport GO:0006811 10 TRPV1 P2RX3 P2RX2 P2RX1 CACNA1A
2 ion transmembrane transport GO:0034220 9.87 TRPV1 P2RX3 P2RX1 CACNA1A
3 chemical synaptic transmission GO:0007268 9.78 P2RX3 P2RX2 CHRM2 CACNA1A
4 response to organic substance GO:0010033 9.71 P2RX3 P2RX2 P2RX1
5 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.7 P2RX1 NGF BCL2L10
6 modulation of chemical synaptic transmission GO:0050804 9.67 P2RX3 NGF CACNA1A
7 cation transmembrane transport GO:0098655 9.61 P2RX3 P2RX2 P2RX1
8 regulation of smooth muscle contraction GO:0006940 9.59 P2RX1 CHRM2
9 cellular response to ATP GO:0071318 9.58 TRPV1 P2RX3
10 positive regulation of calcium-mediated signaling GO:0050850 9.58 P2RX3 P2RX2
11 neuromuscular synaptic transmission GO:0007274 9.58 P2RX3 P2RX2 CACNA1A
12 response to carbohydrate GO:0009743 9.56 P2RX3 P2RX2
13 excitatory postsynaptic potential GO:0060079 9.56 TRPV1 P2RX3 P2RX2 P2RX1
14 regulation of presynaptic cytosolic calcium ion concentration GO:0099509 9.55 P2RX1 CACNA1A
15 response to pain GO:0048265 9.54 TRPV1 TACR1 CACNA1A
16 positive regulation of calcium ion transport into cytosol GO:0010524 9.51 P2RX3 P2RX2
17 response to ATP GO:0033198 9.5 P2RX3 P2RX2 P2RX1
18 peristalsis GO:0030432 9.46 P2RX3 P2RX2
19 purinergic nucleotide receptor signaling pathway GO:0035590 9.33 P2RX3 P2RX2 P2RX1
20 urinary bladder smooth muscle contraction GO:0014832 9.13 TRPV1 P2RX3 P2RX2
21 behavioral response to pain GO:0048266 8.92 TRPV1 P2RX3 P2RX2 CACNA1A

Molecular functions related to Neurogenic Bladder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ion channel activity GO:0005216 9.55 TRPV1 P2RX3 P2RX2 P2RX1 CACNA1A
2 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides GO:0016811 9.26 KLK3 ACER3
3 extracellularly ATP-gated cation channel activity GO:0004931 9.13 P2RX3 P2RX2 P2RX1
4 purinergic nucleotide receptor activity GO:0001614 8.8 P2RX3 P2RX2 P2RX1

Sources for Neurogenic Bladder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....